If PP405 does revive "dead" hair follicles would DHT blockers theoretically be enough to maintain that new hair
    Research/Science 10/14/2025

    From the encyclopedia
    PP405 →

    mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials

    Finasteride →

    Frontline, gold standard treatment for combatting androgenic alopecia

    Dutasteride →

    Heavy duty finasteride that comes with higher risks

    At a glance
    In this question or advice post, the primary subjects mentioned are
    💊 Finasteride (oral)
    💊 Dutasteride (oral)
    💧 Minoxidil (topical)
    the tone is 😐 neutral.

    Other terms

    PP405 may revive dormant hair follicles, and DHT blockers like finasteride or dutasteride could maintain new hair. Combining PP405 with minoxidil might be optimal, but long-term effects and continuous use are uncertain.
    View this post in the Community →

    Similar Community Posts Join

    5 / 5 results

      community Is pp405 actually the cure ? Just how exciting is it ?

       36 upvotes 9 months ago
      PP405 is a promising hair growth stimulant but not a cure for advanced hair loss, as it may only help dormant follicles. Treatments like Minoxidil, Finasteride, and Dutasteride are discussed, with emphasis on early intervention for effectiveness.

      community Haircafe slams pp405 presentation. Are results really that bad?

       64 upvotes 5 months ago
      PP405 shows promise in activating dormant hair follicles and increasing hair counts but lacks detailed efficacy data compared to minoxidil and finasteride. Opinions are mixed, with some optimism and skepticism about its effectiveness.

      community The amazing fast pace of PP405.

      in Chat  327 upvotes 11 months ago
      PP405 is a new hair loss treatment advancing quickly in trials, generating excitement and skepticism about its effectiveness and marketing claims. Some see it as a potential alternative to minoxidil and finasteride, but concerns about long-term effects and the need for DHT blockers persist.

      community Pp405 full presentation on new topical

       106 upvotes 5 months ago
      A new topical treatment, PP405, shows promising results for hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil. However, it may still need to be combined with DHT blockers for optimal results, and its long-term effectiveness remains uncertain.

    Related Research

    6 / 6 results

      research Recent Advances in Drug Development for Hair Loss

      April 2025 in “International Journal of Molecular Sciences”
      This review highlights the limitations of existing hair loss treatments like minoxidil and finasteride and suggests that future therapies may benefit from focusing on antibody and cell-based treatments, which offer targeted and potentially transformative options for managing hair loss disorders.

      research Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique

      March 2025 in “HAL (Le Centre pour la Communication Scientifique Directe)”
      This thesis investigates the underlying mechanisms and treatment options for androgenetic alopecia, highlighting the molecular roles of androgens and genetic predispositions, and evaluates current and emerging therapies, such as PROTACs and Janus Kinase inhibitors, to enhance patient management.

      research PP405 in Alopecia: An Emerging Molecule worth Investigating

      January 2026 in “Journal of Community Medicine and Health Solutions”
      In this study, the novel topical agent PP405 showed favorable tolerability and increased hair density by over 20% in men with advanced androgenetic alopecia after eight weeks, suggesting a promising potential treatment pending further trials.

      research Diagnostic Comparison: SH‑1 Molecule vs PP405 — Safety Profiles in Hair Science

      June 2026 in “HAL (Le Centre pour la Communication Scientifique Directe)”
      This infographic compares the safety profiles of SH‑1, a cosmetic ingredient, which showed no systemic absorption, and PP405, an investigational drug with dose-dependent systemic uptake and potential threshold breaches, highlighting differences in safety between cosmetic and investigational substances according to this report.